News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Sustainability is integral to Biocon's business purpose
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Five batches across four programs of Biocon Academy participated in the graduation ceremony
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
The RCSed's Court of Regents comprises a group of distinguished and accomplished individuals in their field
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
For the year 2022, Biocon bettered its score in all the four EcoVadis themes – Environment (70), Labor & Human Rights (70), Ethics (60), and Sustainable Procurement (60)
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Subscribe To Our Newsletter & Stay Updated
